Clinical Trial Update: First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial [Phase 3]

View source ↗

Summary

A Phase 3 pilot trial evaluated first-line antimetabolite therapy as a steroid-sparing treatment for uveitis; results have been posted after trial completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveitis

Snippet

Sponsor: University of California, San Francisco | Conditions: Uveitis | Phase 3 | Status: COMPLETED | Results posted: 2016-01-05